Remineralizing · Cholecalciferol · CAS 67-97-0
Vitamin D3
C₂₇H₄₄O
Cholecalciferol regulates calcium and phosphorus absorption, controls dentine mineralisation and supports the periodontal immune response — but only through systemic intake, not in a toothpaste.
QDRO position
We use itSystemic agent: effective only when taken orally; topical application in toothpaste has no effect.
Effective concentration
400–2000 IU/day systemic
Typical on market: systemic only
What it is
Vitamin D3 (cholecalciferol) is a fat-soluble steroid prohormone with the formula C₂₇H₄₄O, synthesised in the skin under UVB ultraviolet radiation from the precursor 7-dehydrocholesterol, and also obtained from food (fatty fish, egg yolk, fortified products). Cholecalciferol itself is biologically inactive: in the liver it is converted to calcidiol (25-OH-D), and in the kidneys to the active form calcitriol (1,25(OH)₂D₃).
Calcitriol is a potent nuclear hormone that binds vitamin D receptors (VDR) in more than 200 cell types in the body. For teeth and periodontium, the key locations are VDR in osteoblasts, odontoblasts, keratinocytes and immune cells of the periodontal ligament.
How it works
The primary mechanism is calcium-phosphate homeostasis regulation. Calcitriol increases expression of calcium-binding proteins (calbindin D9k and D28k) in intestinal cells, boosting calcium absorption 2–4 fold. Simultaneously it enhances calcium and phosphorus reabsorption in renal tubules. The result is that ionised calcium and phosphate concentrations in blood and saliva are maintained at levels sufficient for normal mineralisation of dental hard tissues.
The second mechanism is odontoblast and osteoblast stimulation. Calcitriol activates synthesis of osteocalcin and osteopontin — non-collagen matrix proteins of dentine and cementum, ensuring their correct mineralisation. Vitamin D deficiency clinically manifests as dentine hypomineralisation and rachitic changes in hard tissue structure.
The third mechanism is periodontal immunomodulation. VDR in immune cells regulate synthesis of antimicrobial peptides (cathelicidin, beta-defensins), which form the first line of defence for periodontal tissues against pathogens.
Efficacy
The meta-analysis by Hujoel (2013), covering randomised clinical trials from the 1920s–1980s, showed that vitamin D reduces caries incidence by ~50% in deficient children. Observational studies in adults record a correlation between low 25-OH-D (<20 ng/mL) and elevated risk of periodontitis and caries.
The critical caveat: the effect is realised only through systemic intake. Applying cholecalciferol to a tooth surface in a paste delivers no remineralising effect — the molecule is water-insoluble, does not penetrate enamel and does not interact with apatite. Inclusion in toothpaste is a marketing exercise without real action.
Safety
Cholecalciferol is safe at physiological doses. Recommended daily intake: 600–800 IU/day for adults, 400 IU/day for children. Upper tolerable intake level: 4000 IU/day (USA, Europe). Toxicity (hypercalcaemia) occurs with prolonged intake above 10,000 IU/day. Vitamin D deficiency is diagnosed in approximately 40% of the Russian population, especially in northern regions during winter.
Role in the QDRO formula
In QDRO toothpastes, vitamin D3 is not used — its inclusion would be declarative, not functional. However, the topic of systemic vitamin D is an important educational touchpoint for the v.pro audience.
A prospective direction for the brand: the QDRO nutraceutical complex "Second Enamel from Within" (D3 + K2 + calcium) as a complement to topical care — a synergistic pairing that no player in the Russian oral care market has yet built.